CD19/CD20 bicistronic CAR-T cells therapy (Kite Pharma)

N/A

Report date: 2026/05/13 20:02:10

Base Information

Drug NameCD19/CD20 bicistronic CAR-T cells therapy (Kite Pharma)

Drug Alias NameKITE-753

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD20

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesNetherlandsAustralia +[5]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesKite Pharma

China Registration ClassN/A

Develop Information

Active CompaniesKite Pharma

Inactive CompaniesN/A

Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A